◌
Bioelectronics
Adaptive stimulation, multimodal sensing and bioelectronic interaction.
Aurealix
AdaptiveBioelectronic and BiopharmaceuticalTechnologies. AdaptiveBioelectronic andBiopharmaceuticalTechnologies.
Bioelectronics. Adaptive therapeutics. Probabilistic control.
Aurealix develops adaptive technology architectures for bioelectronic interaction, neurocartographic mapping and probabilistic therapeutic control across MedTech and Biopharma.
◎
Neurocartography
Functional response mapping for personalized neuromodulation and stimulation planning.
↗
Biopharma
Probabilistic in vivo delivery, proteostasis concepts and hazard-function logic.
✓
Validation
First validation pathways focus on measurable, clinically relevant use cases.
Technology
One adaptive intelligence core. Two development pillars.
Aurealix is structured around a shared adaptive decision architecture with two complementary pillars: bioelectronic MedTech and biopharmaceutical therapeutic control.
Pillar I
Bioelectronic MedTech.
Neurocartography, adaptive stimulation concepts and bioelectronic systems with spatiotemporal activation patterns, response-phase logic and physiological feedback.
Pillar II
Biopharmaceutical systems.
Probabilistic in vivo delivery for substances with physiological activity, using proteostasis modelling, tipping-point concepts, adaptive therapeutic logic and hazard functions.
Initial validation pathway
Acute and chronic pain relief.
Acute and chronic pain relief is positioned as the first clinical validation pathway for Aurealix's adaptive bioelectronic technologies.
The goal is to translate adaptive stimulation, neurocartographic response mapping and probabilistic control into measurable physiological outcomes, while preserving a broader roadmap for neuromodulation and adaptive therapeutics.
Intellectual property
Fifteen patent filings across adaptive technologies.
Aurealix is supported by a portfolio of fifteen patent filings spanning adaptive bioelectronic systems, neurocartographic knowledge models, probabilistic physiological control and adaptive therapeutic architectures.
Collaboration
Academic, clinical and industrial partners.
Aurealix welcomes discussions with universities, research institutes, clinical partners, technology companies and consortium initiatives interested in validation and translational development.
Identity